Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Leukemia. 2009 Feb 26;23(8):1410–1416. doi: 10.1038/leu.2009.30

Figure 1. AML97 treatment schema.

Figure 1

Patients were randomized to receive cladribine and daily 2-hour infusions (Arm A) or a continuous infusion (Arm B) of cytarabine. The second and third courses of chemotherapy consisted of daunorubicin, cytarabine, and etoposide (DAV). Further therapy was based on risk status and the availability of a matched sibling donor.